Chercheur, Institut Douglas
serge_dot_gauthier_At_mcgill_dot_ca |
2002
Erkinjuntti T., Gauthier S. (2002). Vascular causes of cognitive impairment - the perspective . Dans Erkunjutti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 643-651). Martin Dunitz Ltd.
Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C. V. (2002). Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial, Lancet, 359(9314), 1283-90.
Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E., et al. (2002). The efficacy and safety of donepezil in patients with moderate to severe Alzheimer's disease, Res Pract Alzheimer Dis, 6, 302-307.
Ferris S., Gauthier S. (2002). Cognitive Outcome Measures in Vascular Dementia . Dans Erkinjuntti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 395-400). Martin Dunitz Ltd.
Gauthier S. (2002). Current and future therapeutic strategies for Alzheimer's disease and related dementias, Expert Rev Neurother, 2(3), 277-8.
Gauthier S. (2002). Diagnostic instruments to assess functional Impairment . Dans Qizilbash N., Schneider L., Brodaty H., Tariot P., Kaye J., Chui H., Erkinjuntti T. & Qizilbash N. (Éds.) , Evidence-based dementia practice (pp. 101-105). Blackwell Science Ltd.
Gauthier S. (2002). Clinical aspects . Dans Mulligan R., Van der Linden M., Juillerat A.-C. & Mulligan R. (Éds.) , The clinical management of early Alzheimer's disease : a handbook . Erlbaum.
Gauthier S. (2002). Advances in the pharmacotherapy of Alzheimer's disease, CMAJ, 166(5), 616-23.
Gauthier S., Feldman H., Hecker J., Vellas B., Ames D., Subbiah P., Whalen E., Emir B. (2002). Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease, Int Psychogeriatr, 14(4), 389-404.
Gauthier S., Feldman H., Hecker J., Vellas B., Emir B., Subbiah P. (2002). Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease, Curr Med Res Opin, 18(6), 347-54.
Gauthier S., Grundman M. (2002). Alzheimer's disease: trial designs to establish disease modification . Dans Gauthier S. & Cummings J. L. (Éds.) , Alzheimer's Disease and Related Disorders Annual (pp. 77-85). Martin Dunitz Ltd.
Gauthier S., Gélinas I. (2002). Evaluation of daily activities in vascular cognitive impairment . Dans Erkunjutti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 411-416). Martin Dunitz Ltd.
Joober R., Gauthier S., Lal S., Bloom D., Lalonde P., Rouleau G., Benkelfat C., Labelle A. (2002). Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test, Arch Gen Psychiatry, 59(7), 662-3.
Law A., O'Donnell J., Gauthier S., Quirion R. (2002). Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats, Neuroscience, 112(2), 267-75.
Panisset M., Gauthier S., Moessler H., Windisch M. (2002). Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent, J Neural Transm, 109(7-8), 1089-104.
Rockwood K., Gauthier S., Erkinjuntti T. (2002). Prevention and treatment of vascular dementia . Dans Erkunjutti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 587-595). Martin Dunitz Ltd.
Sibley A., MacKnight C., Rockwood K., Fisk J., Gauthier S., Guzman D. A., Hogan D. B. (2002). The effect of the living situation on the severity of dementia at diagnosis, Dement Geriatr Cogn Disord, 13(1), 40-5.